Yann Godbert

2.9k total citations
45 papers, 841 citations indexed

About

Yann Godbert is a scholar working on Endocrinology, Diabetes and Metabolism, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Yann Godbert has authored 45 papers receiving a total of 841 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Endocrinology, Diabetes and Metabolism, 16 papers in Pulmonary and Respiratory Medicine and 11 papers in Oncology. Recurrent topics in Yann Godbert's work include Thyroid Cancer Diagnosis and Treatment (32 papers), Lung Cancer Treatments and Mutations (9 papers) and Cancer Diagnosis and Treatment (5 papers). Yann Godbert is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (32 papers), Lung Cancer Treatments and Mutations (9 papers) and Cancer Diagnosis and Treatment (5 papers). Yann Godbert collaborates with scholars based in France, Italy and United States. Yann Godbert's co-authors include F. Bonichon, Sophie Leboulleux, Martin Schlumberger, Isabelle Soubeyran, Isabelle Borget, Gaëlle Pérot, Isabelle Hostein, Camille Buffet, Antoîne Italiano and Frédéric Chibon and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Yann Godbert

41 papers receiving 833 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yann Godbert France 14 614 226 190 168 142 45 841
Trisha M. Shattuck United States 8 249 0.4× 377 1.7× 133 0.7× 173 1.0× 294 2.1× 13 902
김나래 2 559 0.9× 412 1.8× 55 0.3× 358 2.1× 85 0.6× 3 1.0k
Barbara Gazić Slovenia 13 193 0.3× 140 0.6× 80 0.4× 130 0.8× 67 0.5× 45 506
Yulia Strenov Israel 13 150 0.2× 194 0.9× 74 0.4× 145 0.9× 37 0.3× 19 622
O Ippolito Italy 8 674 1.1× 114 0.5× 30 0.2× 295 1.8× 77 0.5× 11 789
Chi‐Chung Tong China 13 96 0.2× 271 1.2× 136 0.7× 230 1.4× 28 0.2× 31 590
Pradeep Thanigaimani United States 7 129 0.2× 503 2.2× 175 0.9× 200 1.2× 22 0.2× 11 669
Jacek Sygut Poland 13 146 0.2× 142 0.6× 175 0.9× 200 1.2× 23 0.2× 45 496
Rieke Fischer Germany 9 79 0.1× 503 2.2× 270 1.4× 62 0.4× 67 0.5× 33 675
C. Chougnet France 17 689 1.1× 794 3.5× 92 0.5× 479 2.9× 75 0.5× 36 1.6k

Countries citing papers authored by Yann Godbert

Since Specialization
Citations

This map shows the geographic impact of Yann Godbert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yann Godbert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yann Godbert more than expected).

Fields of papers citing papers by Yann Godbert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yann Godbert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yann Godbert. The network helps show where Yann Godbert may publish in the future.

Co-authorship network of co-authors of Yann Godbert

This figure shows the co-authorship network connecting the top 25 collaborators of Yann Godbert. A scholar is included among the top collaborators of Yann Godbert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yann Godbert. Yann Godbert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cao, Christine Do, Yann Godbert, Stéphane Bardet, et al.. (2025). ENDOCAN TUTHYREF network consensus recommendations: Refractory follicular-derived thyroid cancer. Annales d Endocrinologie. 86(4). 101735–101735.
2.
Lasolle, Hélène, Christine Do Cao, Livia Lamartina, et al.. (2025). ENDOCAN-TUTHYREF network consensus recommendations. Refractory medullary thyroid cancer. Annales d Endocrinologie. 86(4). 101733–101733.
3.
Lasolle, Hélène, Livia Lamartina, Camille Buffet, et al.. (2024). Patients with medullary thyroid carcinoma and long term treatment with vandetanib: a study from the endocan -tuthyref network. Endocrine Abstracts. 1 indexed citations
4.
5.
Wirth, Lori J., Marcia S. Brose, Eric J. Sherman, et al.. (2021). Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. Journal of Clinical Oncology. 39(21). 2359–2366. 83 indexed citations
6.
Wirth, Lori J., Eric J. Sherman, Bruce Robinson, et al.. (2021). O10-3 Selpercatinib (LOXO-292) in patients (pts) with RET-altered thyroid cancer. Annals of Oncology. 32. S289–S289. 1 indexed citations
7.
Fouchardière, Christelle de la, Johanna Wassermann, Fabien Calcagno, et al.. (2021). Génotypage moléculaire dans les cancers réfractaires de la thyroïde en 2021 : quand, comment, et pourquoi ? Un travail du réseau TUTHYREF. Bulletin du Cancer. 108(11). 1044–1056. 8 indexed citations
8.
9.
Fouchardière, Christelle de la, Yann Godbert, Cécile Dalban, et al.. (2021). Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR. European Journal of Cancer. 157. 153–164. 11 indexed citations
10.
Newbold, K., Baktiar Hasan, Laura D. Locati, et al.. (2020). 1919P Nintedanib (BIBF1120) after first line therapy in progressive medullary thyroid cancer: A multicenter EORTC prospective randomized double-blind phase II study (NCT01788982). Annals of Oncology. 31. S1087–S1088. 1 indexed citations
11.
Lamartina, Livia, Yann Godbert, Christine Do Cao, et al.. (2020). Locally unresectable differentiated thyroid cancer: outcomes and perspectives. Endocrine. 69(1). 133–141. 12 indexed citations
12.
Schlumberger, Martin, Sophie Leboulleux, Bogdan Catargi, et al.. (2018). Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. The Lancet Diabetes & Endocrinology. 6(8). 618–626. 103 indexed citations
13.
Berdelou, A., Isabelle Borget, Yann Godbert, et al.. (2017). Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice. Thyroid. 28(1). 72–78. 102 indexed citations
14.
15.
Godbert, Yann, et al.. (2016). 18F-DOPA PET/CT in Orbital Metastasis From Medullary Thyroid Carcinoma. Clinical Nuclear Medicine. 41(6). e296–e297. 2 indexed citations
16.
Bonichon, F., Xavier Buy, Yann Godbert, et al.. (2015). Local treatment of metastases from differentiated thyroid cancer. Annales d Endocrinologie. 76(1). 1S40–1S46. 19 indexed citations
17.
Bonichon, F., Yann Godbert, Afshin Gangi, Xavier Buy, & Jean Palussière. (2015). PET/Computed Tomography and Thermoablation (Radiofrequency, Microwave, Cryotherapy, Laser Interstitial Thermal Therapy). PET Clinics. 10(4). 519–540. 3 indexed citations
18.
Pérot, Gaëlle, Isabelle Soubeyran, Agnès Ribeiro, et al.. (2014). Identification of a Recurrent STRN/ALK Fusion in Thyroid Carcinomas. PLoS ONE. 9(1). e87170–e87170. 61 indexed citations
19.
Godbert, Yann, Isabelle Soubeyran, Philippe Lagarde, et al.. (2013). Brain Metastases from Thyroid Carcinoma: A Retrospective Study of 21 Patients. Thyroid. 24(2). 270–276. 54 indexed citations
20.
Meyer, Marie, et al.. (2013). Benign Cystic Mesothelioma. Clinical Nuclear Medicine. 39(9). e395–e397. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Trisha M. Shattuck Breakdown of academic impact, for papers by 김나래 Breakdown of academic impact, for papers by Barbara Gazić Breakdown of academic impact, for papers by Yulia Strenov Breakdown of academic impact, for papers by O Ippolito Breakdown of academic impact, for papers by Chi‐Chung Tong Breakdown of academic impact, for papers by Pradeep Thanigaimani Breakdown of academic impact, for papers by Jacek Sygut Breakdown of academic impact, for papers by Rieke Fischer Breakdown of academic impact, for papers by C. Chougnet
Rankless by CCL
2026